Manvinder Banga - GlaxoSmithKline PLC Non-Executive Director

GSK Stock  USD 42.87  0.12  0.28%   

Director

Mr. Manvinder Singh Banga is Senior NonExecutive Independent Director of the Company since May 5, 2016. Prior to joining GSK, Vindi spent 33 years at Unilever plc, where his last role was President of the Global Foods, Home and Personal Care businesses, and he was a member of the Unilever Executive Board. Vindi sat on the Prime Minister of Indias Council of Trade Industry from 2004 to 2014, and was on the Board of Governors of the Indian Institute of Management, Ahmedabad. Vindi is also the recipient of the Padma Bhushan, one of Indias highest civilian honours. Between 2015 and 2016, Vindi was a NonExecutive Director of Thomson Reuters Corporationrationand a member of its HR committee. Vindi was also previously Chairman of the Supervisory Board of Mauser Group. Vindi is a Partner at private equity investment firm Clayton Dubilier Rice. He is also Chairman of Kalle GmbH, Senior Independent Director of Marks Spencer Group plc, a member of its Nomination Committee and Chairman of its Remuneration Committee. Vindi is a NonExecutive Director of the Confederation of British Industry, a Director of High Ridge Brands Co, a member of the Holdingham International Advisory Board and Chair of the Board of Trustees of Marie Curie. He is also on the Governing Board of the Indian School of Business, Hyderabad, and is a member of the Indo UK CEO Forum. since 2016.
Age 62
Tenure 8 years
Address 980 Great West Road, Brentford, United Kingdom, TW8 9GS
Phone44 20 8047 5000
Webhttps://www.gsk.com

GlaxoSmithKline PLC Management Efficiency

The company has Return on Asset of 0.0881 % which means that on every $100 spent on assets, it made $0.0881 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4638 %, implying that it generated $0.4638 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlaxoSmithKline PLC's Return On Assets are quite stable compared to the past year. Return On Equity is expected to rise to 0.42 this year, although the value of Return On Capital Employed will most likely fall to 0.18. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.
The company has 18.02 B in debt with debt to equity (D/E) ratio of 0.98, which is OK given its current industry classification. GlaxoSmithKline PLC ADR has a current ratio of 1.4, which is typical for the industry and considered as normal. Debt can assist GlaxoSmithKline PLC until it has trouble settling it off, either with new capital or with free cash flow. So, GlaxoSmithKline PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GlaxoSmithKline PLC ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GlaxoSmithKline to invest in growth at high rates of return. When we think about GlaxoSmithKline PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Michael WhiteBank Of America
69
Ulrich SchmidtAlcoa Corp
65
Carl WareChevron Corp
70
Kathryn FullerAlcoa Corp
73
Leo ReifAlcoa Corp
64
Robert YostBank Of America
73
Henrietta ForeExxon Mobil Corp
67
James NevelsAlcoa Corp
69
Linda WolfWalmart
66
Debra ReedKlagesChevron Corp
63
Walter MasseyMcDonalds
77
Sarah FriarWalmart
47
Alice GastChevron Corp
61
Martin SorrellAlcoa Corp
70
Inge ThulinChevron Corp
64
Amy AlvingAlcoa Corp
N/A
Dambisa MoyoChevron Corp
52
Pierre WeckBank Of America
70
Jack BovenderBank Of America
74
Steven ReinemundExxon Mobil Corp
72
TimothyWalmart
58
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Gsk Plc is traded on New York Stock Exchange in the United States. GlaxoSmithKline PLC ADR (GSK) is traded on New York Stock Exchange in USA. It is located in 980 Great West Road, Brentford, United Kingdom, TW8 9GS and employs 70,212 people. GlaxoSmithKline PLC is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

GlaxoSmithKline PLC ADR Leadership Team

Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Daniel Podolsky, Non-Executive Independent Director
Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
CA BSc, President Development
Philip Thomson, President Affairs
Roy Anderson, Non-Executive Independent Director
Bill Louv, Senior Vice President - Core Business Services
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President, Group General Counsel, Legal and Compliance
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Shobie Ramakrishnan, Chief Digital and Technology Officer
Sarah EltonFarr, Head Relations
Stephanie Burns, Non-Executive Independent Director
Julie Brown, Chief Officer
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Anne Beal, Non-Executive Independent Director
Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert
Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert
Victoria Whyte, Company Secretary
Tony Wood, Chief Scientific Officer - Designate
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital and Technology Officer

GlaxoSmithKline Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.03
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.